Genmab: gets EU marketing approval for multiple myeloma drug

(CercleFinance.com) - Denmark's Genmab said that the European Commission has granted marketing authorisation for the cancer drug Darzalex for the treatment of patients with multiple myeloma.


This approval does not come as a surprise, as it follows a positive opinion made by a European medicines agency panel in April 2020. As a matter of fact, the Genmab share was down 1.8% in Copenhagen after the announcement.

Darzalex has already received US FDA approval to treat multiple myeloma.

The drug - which triggers a person's own immune system to attack the cancer cells, resulting in rapid tumor cell death - is being marketed by Johnson & Johnson's Janssen unit under an exclusive worldwide license with Genmab.

Copyright (c) 2020 CercleFinance.com. All rights reserved.